Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Public health and health economics

4331 - EMA support for early access for oncology products


08 Oct 2016


Public health and health economics


Steffen Thirstrup


Annals of Oncology (2016) 27 (6): 474-482. 10.1093/annonc/mdw387


S. Thirstrup

Author affiliations

  • Nda Advisory Board, NDA Advisory Services Ltd, KT22 9DF - Leatherhead/GB


Abstract 4331


Access to new, innovative, medicines potentially fulfilling unmet medical needs are of paramount importance to patients. European patients will on average have to wait 6 to12 months as compared to their US counterparts to get access to new anti-cancer products. While the US FDA have introduced a number of procedures to shorten the review time, the European Medicines Agency has only recently embarked upon such efforts.


Following years of discussion on what has been termed 'adaptive licensing', the European Medicines Agency (EMA) launched a new process in March 2016 to support development, and potentially faster regulatory review and approval time was introduced by the EMA. The process has been termed PRIME (PRIority MEdicine) and contains a number of changes to the traditional sponsor-agency relationship.


PRIME includes early access to EMA scientific advice as well as early appointment of the future EU rapporteur who will be leading the regulatory review of any future marketing authorisation. For small/medium size companies as well as academic institutions developing new medicines, access to scientific advice (at reduced or fully waived fee) will be possible at the stage of 'proof of principle' (i.e. prior to Phase 1) whereas large pharma can enter the scheme at the stage of 'proof of concept' (i.e. around Phase 2).


The PRIME scheme was launched in spring 2016 and a number of projects were selected as appropriate for inclusion. Whether this process will lead to earlier access to new, innovative medicines for patients with clear unmet medical need is too early to say. At any rate, this process is the first attempt by EU regulators to optimise the use of the current medicines legislation to foster innovation and hopefully improve review time for medicines in areas with high unmet medical needs such as oncology.

Clinical trial identification


Legal entity responsible for the study



NDA Advisory Services Ltd


S. Thirstrup: I work as a full-time employee for NDA Advisory Services Ltd, which is a global scientific and regulatory consultancy firm for the pharmaceutical industry. I do not receive any direct payment for my work from pharmaceutical developers and/or manufacturers.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings